Oxcarbazepine Tablet, Film Coated
Product Images NDC 60429-061

8 FDA label images from Golden State Medical Supply, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 60429-061). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Oxcarbazepine 01)

Chemical Structure (Oxcarbazepine 01)
Chemical structure diagram of the active ingredient oxcarbazepine, showing its molecular framework including a dibenzazepine core and functional groups.*
FDA Label Image

Figure 1 (Oxcarbazepine 02)

Figure 1 (Oxcarbazepine 02)
A line graph showing the exit rate over time in days from Day 2 to Day 11 in a clinical trial. Two treatment groups are represented: Oxcarbazepine (solid line) and Placebo (dotted line). The graph includes a log-rank test with a p-value of 0.0001, indicating statistical comparison between groups.*
FDA Label Image

Figure 2 (Oxcarbazepine 03)

Figure 2 (Oxcarbazepine 03)
A Kaplan-Meier curve chart comparing seizure rates over time from first dose to first seizure between treatment groups receiving Oxcarbazepine and placebo. The x-axis represents days from first dose to first seizure (0 to 140 days), and the y-axis shows seizure rate (0 to 1). The plot includes a log-rank test with p-value of 0.046.*
FDA Label Image

Figure 3 (Oxcarbazepine 04)

Figure 3 (Oxcarbazepine 04)
A survival curve chart displaying exit rates over time in days for two treatment groups labeled HIGH and LOW. The x-axis shows time to exit (days) from 0 to 130, and the y-axis shows exit rate from 0.0 to 1.0. A log-rank test p-value of 0.0001 is indicated, suggesting a statistically significant difference between the groups.*
FDA Label Image

Figure 4 (Oxcarbazepine 05)

Figure 4 (Oxcarbazepine 05)
A Kaplan-Meier curve depicting exit rates over time (days) for two treatment groups labeled HIGH and LOW. The X-axis represents time to exit in days, and the Y-axis shows the exit rate from 0 to 1. The LOW group shows a steeper increase in exit rate compared to the HIGH group. The graph includes a log-rank test p-value of 0.0001 indicating statistical significance.*
FDA Label Image

60429-061-05lb- Oxcarbazepine 150 Gm (Rev. 0124.jpg)

60429-061-05lb- Oxcarbazepine 150 Gm (Rev. 0124.jpg)
Label for Oxcarbazepine 150 mg film-coated tablets, USP, marketed by Golden State Medical Supply, Inc. The label indicates a package size of 500 tablets and includes storage instructions, a barcode, and a note on the use of FD&C Yellow No. 5 as a color additive.*
FDA Label Image

60429-062-05lb- Oxcarbazepine 300 Gm (Rev. 0124.jpg)

60429-062-05lb- Oxcarbazepine 300 Gm (Rev. 0124.jpg)
Label for OXcarbazepine 300 mg film coated tablets, USP, by Golden State Medical Supply, Inc. The label indicates a package size of 500 tablets, with instructions to dispense a medication guide and storage conditions. It includes warnings about color additives and child safety. The label also displays NDC 60429-062-05 and a barcode.*
FDA Label Image

60429-063-05lb- Oxcarbazepine 600 Gm (Rev. 0124.jpg)

60429-063-05lb- Oxcarbazepine 600 Gm (Rev. 0124.jpg)
Label for OXcarbazepine 600 mg film-coated tablets by Golden State Medical Supply, Inc., containing 500 tablets. The label includes the NDC 60429-063-05, barcode, and key storage instructions. It notes the presence of FD&C Yellow No. 5 as a color additive and provides a link for the medication guide.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.